{"id":526812,"date":"2021-08-11T16:08:19","date_gmt":"2021-08-11T20:08:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gbs-inc-reports-fourth-quarter-and-full-year-2021-preliminary-financial-results-and-recent-business-highlights\/"},"modified":"2021-08-11T16:08:19","modified_gmt":"2021-08-11T20:08:19","slug":"gbs-inc-reports-fourth-quarter-and-full-year-2021-preliminary-financial-results-and-recent-business-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gbs-inc-reports-fourth-quarter-and-full-year-2021-preliminary-financial-results-and-recent-business-highlights\/","title":{"rendered":"GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights"},"content":{"rendered":"
\n

\n – Awarded $4.7 Million Government Grant Funding to support the building of a\u00a0<\/em>
\n high-tech manufacturing facility –<\/em>\n <\/p>\n

\n – Signs Strategic Partnerships with Johns Hopkins University, Wyss Institute from Harvard University, University of Newcastle and Precision Medical Architects –<\/em>\n <\/p>\n

\n – $12.7 Million in Cash, Cash Equivalents, and Marketable Securities as of\u00a0<\/em>
\n June 30, 2021, Provides Runway into 4Q 2022 \u2013 <\/em>\n <\/p>\n

-To Host Conference Call and Webcast Today at 4:30 p.m. ET-<\/p>\n

NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) — GBS Inc.<\/a> (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point-of-care, today announced its financial results for the fourth financial quarter and full-year ended June 30, 2021, and provided a recent business update. Management will host a webcast and conference call at 4:30 p.m. today after market.<\/p>\n

\u201cThis has been a tremendous year for GBS marked by advances in our regulatory affairs, IRB approval to commence clinical studies, strategic partnerships and financial management. We, as a company, are driven to provide non-invasive, real-time diagnostics testing solutions to patients and their healthcare providers at point-of-care as GBS leverages its core Biosensor Platform technology,\u201d Chief Executive Officer of GBS, Harry Simeonidis said.<\/p>\n

\u201cWe have made great progress towards commercializing our novel saliva-glucose test and the opportunities to expand our pipeline are very exciting. Most recently, a grant from the Australian Federal Government to financially support our next-generation high-tech manufacturing facility highlights the confidence others see in our technology and approach. Our technology was one of six National Manufacturing Priorities identified by the Government under Modern Manufacturing Strategy.\u201d<\/p>\n

\n Fourth Quarter & FY Highlights and Recent Operational Developments<\/strong>\n <\/p>\n

\n Financial Stability<\/strong>\n <\/p>\n